Výsledky vyhledávání

Akademický článek

Protocol for the EACH trial: a multicentre phase II study evaluating the safety and antitumour activity of the combination of avelumab, an anti-PD-L1 agent, and cetuximab, as any line treatment for patients with recurrent/metastatic head and neck squamous cell cancer (HNSCC) in the UK

Autor: Martin Forster, Joseph Sacco, Kenrick Ng, Laura White, Anthony Kong, Joseph Ward, Helen Lowe, John Hartley, Graham Wheeler, Rob Metcalf, Sharon Forsyth, Reshma Bhat, Leah Ensell, Victoria Spanswick, Elizabeth Lloyd-Dehler

Publikováno v: BMJ Open, Vol 13, Iss 11 (2023)

Introduction Head and neck cancer is the eighth most common cancer in the UK. Current standard of care treatment for patients with recurrent/metastatic squamous cell head and neck carcinoma (HNSCC) is platinum-based chemotherapy combined with the ant

Externí odkaz: https://doaj.org/article/acaa972a798b44c29804e370110c94d8

Zobrazit plný text záznamu

Repeat serological testing for anti-citrullinated peptide antibody after commencement of therapy is not helpful in patients with seronegative rheumatoid arthritis

Autor: Les Cleland, Mihir D. Wechalekar, Leah McWilliams, Michael D. Wiese, Christopher Hill, Alistair B. Reid, Cindy Hall, Susanna Proudman, Anita Lee, Rob Metcalf

Aim: To Investigate the prevalence of seroconversion to ACPA after commencement of triple disease-modifying anti-rheumatic drug (DMARD) treat-to-target therapy. Background: Anti-citrullinated peptide antibody (ACPA) and rheumatoid factor (RF) define

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e58dcc4b4c65fc0b24bac0b1d838d5f
https://hdl.handle.net/11541.2/143684

Zobrazit plný text záznamu

Real-world trends in costs of next generation sequencing (NGS) testing in U.S. setting

Autor: Gillian W. Hooker, Sumesh Kachroo, Rob Metcalf, Kaushal Desai, Caiqian Cropper, Katri Gilbert

Publikováno v: Journal of Clinical Oncology. 39:e18824-e18824

e18824 Background: Recent advances in NGS testing have revolutionized the scope for personalized medicine. The goal of this study was to describe historic trends in the average allowed cost for NGS testing. Methods: This was a retrospective database

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::41738a22ac813949c7c5bab853e638ab
https://doi.org/10.1200/jco.2021.39.15_suppl.e18824

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání